Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Diluted Average) (2018 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Shares Outstanding (Diluted Average) for 10 consecutive years, with $161.0 million as the latest value for Q1 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 2.08% to $161.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $161.0 million through Mar 2025, up 2.08% year-over-year, with the annual reading at $160.7 million for FY2020, 2.97% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $161.0 million in Q1 2025 for Ironwood Pharmaceuticals, up from $158.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $161.0 million in Q1 2025 to a low of $155.4 million in Q2 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $158.1 million across 3 years, with a median of $158.0 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 1.92% in 2024 and later grew 2.08% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $155.4 million in 2023, then increased by 1.92% to $158.4 million in 2024, then increased by 1.65% to $161.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for IRWD at $161.0 million in Q1 2025, $158.4 million in Q2 2024, and $157.7 million in Q1 2024.